-+ 0.00%
-+ 0.00%
-+ 0.00%

Fractyl Health posts REMAIN-1 midpoint cohort presentation on Revita weight maintenance after GLP-1 discontinuation

PUBT·07/15/2026 10:02:45
Listen to the news
Fractyl Health posts REMAIN-1 midpoint cohort presentation on Revita weight maintenance after GLP-1 discontinuation
  • Fractyl Health highlighted one-year REMAIN-1 midpoint cohort data showing higher post-GLP-1 weight-loss retention with Revita than sham.
  • Optimized subgroup showed up to 84% of weight loss retained with Revita versus 46% with sham at 12 months.
  • Complete ablation over 14 cm drove durability, with 81% retention in Revita versus 48% in sham in that population.
  • Safety profile remained clean through 12 months, with no device-related serious adverse events; any treatment-emergent adverse events were similar to sham.
  • REMAIN-1 pivotal cohort is fully randomized; topline 6-month data targeted for early Q4 2026, with a potential FDA De Novo submission in late Q4 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fractyl Health Inc. published the original content used to generate this news brief on July 15, 2026, and is solely responsible for the information contained therein.